REPLIGEN CORP acquires ARTeSYN Biosolutions Holdings Ireland Limited
The deal at a glance
REPLIGEN CORP acquired ARTeSYN Biosolutions Holdings Ireland Limited for ~$200 million (~$130M cash + ~$70M in Repligen stock), a transaction completed in December 2020, structured as combination (cash plus stock).
ARTeSYN Biosolutions Holdings Ireland Limited operates in Systems / Chromatography & Filtration, is based in Ireland (with U.S. operations), had revenue of about ~$30 million projected annual revenue. Acquisition of ARTeSYN Biosolutions, a maker of gold-standard single-use downstream bioprocessing systems including automated chromatography and filtration systems with unique single-use flow-path designs. The deal advanced Repligen's Systems strategy in Filtration and Chromatography, complementing TangenX flat-sheet cassettes and OPUS pre-packed columns. ARTeSYN was projected to generate ~$30 million in revenue.
Hunt said 'the addition of ARTeSYN Biosolutions and Non-Metallic Solutions further strengthens our Systems offering. The ARTeSYN portfolio expands on the market success of our hollow-fiber and flat-sheet products.'
Gold-standard single-use downstream bioprocessing systems anchoring the Systems franchise. Complements TangenX cassettes and OPUS columns; advances single-use Systems strategy. Repligen Systems
No advisory firms have been disclosed for this transaction.